Roy Lee Mason, Pharm D
About Roy Lee Mason, Pharm D
Roy Lee Mason, Pharm D, serves as the National Director of Provider Solutions at Mirati Therapeutics, a position he has held since 2022. He has a diverse background in pharmacy and health outcomes, with previous roles at GSK and CHRISTUS Trinity Mother Frances Health System.
Work at Mirati Therapeutics
Roy Lee Mason serves as the National Director of Provider Solutions at Mirati Therapeutics. He has held this position since 2022 and is responsible for developing and implementing strategies that enhance provider engagement and optimize patient access to therapies. His role focuses on aligning provider solutions with the company's mission to advance innovative treatments in oncology.
Education and Expertise
Roy Lee Mason has a comprehensive educational background in pharmacy and biological sciences. He earned a Doctor of Pharmacy (Pharm.D.) from the University of Florida from 2000 to 2003. Prior to this, he completed a Bachelor of Pharmacy (BPharm) at Southwestern Oklahoma State University from 1992 to 1994. He also holds a Bachelor of Science (BS) in Biology from West Texas A&M University, which he completed from 1981 to 1986. Additionally, he studied Pre-Pharmacy at Texas Tech University from 1990 to 1991.
Professional Background
Roy Lee Mason has extensive experience in the pharmaceutical industry. He worked as a Clinical Pharmacist at CHRISTUS Trinity Mother Frances Health System in Tyler, Texas, from 2000 to 2010. He later joined Tesaro/GSK as Director of Strategic Account Operations, where he worked from 2017 to 2022. Prior to his current role, he served as the National Health Outcomes Liaison at GSK from 2020 to 2022.
Career Progression
Roy Lee Mason's career reflects a steady progression through various roles in the pharmaceutical sector. After starting as a Clinical Pharmacist, he transitioned to strategic roles at Tesaro/GSK, where he focused on account operations. His experience at GSK as a National Health Outcomes Liaison further enhanced his expertise in health outcomes and provider solutions, leading to his current position at Mirati Therapeutics.